Sifted – How AI startups working on clinical trials for cancer could find a breakthrough before big pharma

This article from Sifted features our Innovation Fund’s strategic investments in Genialis and Nucleai.

Learn about our collaborations with these two startups, leading the change in using artificial intelligence to discover predictive biomarkers and map complex cellular interactions. These efforts are paving the way towards improved clinical trial success rates.

These initiatives highlight the pivotal role of our Innovation Fund in advancing AI technologies in healthcare, particularly in oncology. By bridging startups like Genialis and Nucleai with the pharmaceutical industry, the Fund accelerates innovation with agile approaches to tackle complex medical challenges. This collaborative approach not only has the potential to speed up drug development, but also catalyzes transformative advancements in precision medicine, delivering more effective solutions for patients.

Discover more here.